Dengue: Malaysia and Philippines still raise alarm in experienced region:
This article was originally published in Clinica
Executive Summary
Outbreaks of dengue fever in Malaysia and the Philippines have raised concern due to the unusually high number of cases, appearing to confirm fears expressed by the WHO last week over trends for 2007 (full report tomorrow). Malaysia recorded 4,100 cases in January (including 13 deaths), according to Taiwan's Centre for Disease Control (CDC); the total in 2006 was 34,400, with 70 deaths. Philippine health officials, meanwhile, expressed alarm at the high rates recorded last month, confirming 189 (and four deaths) at one hospital (San Lazaro) alone. Elsewhere, Singapore reported almost 280 cases, compared to just over 3,000 in 2006; in China (3,500 in 2006), Taiwan and Hong Kong have had 87 and two cases, respectively.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.